The problem with Kurzweil is he vastly overestimates the speed at which biotech is evolving. The pace of new medical and drug developments for example is absol

The problem with Kurzweil is he vastly overestimates the speed at which biotech is evolving. The pace of new medical and drug developments for example is absolutely glacial (see Eroom's law[1]) and has been costing more and more every year. Yes, this is partially a regulation problem. However all the fantasy stuff that he proposes with regard to brain computer integration is not going to happen anytime soon at the pace that things are going. Also, his belief in the feasibility of reversible computing is pretty optimistic. [1] http://pipeline.corante.com/archives/2012/03/08/erooms_law.php http://pipeline.corante.com/archives/2012/03/08/erooms_law.p...